Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.

Episode 26 December 07, 2022 00:39:02
Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.
Few & Far Between: Conversations from the Front Lines of Drug Development
Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.

Dec 07 2022 | 00:39:02

/

Show Notes

"Try to find the people who have a really strong background in regulatory science, who really understand the fundamentals, and who you believe can think creatively about the challenges of the cell therapy space." - Chris Min, Longeveron

Biorasi welcomes Chris Min to the Few & Far Between podcast for an inside look at the cell therapy industry and the importance of finding the right team to support your clinical trials. 

Other Episodes

Episode 17

January 12, 2022 00:39:58
Episode Cover

Episode 17: Amy Fenton Parker, President and CEO at Batten Disease Support and Research Organization (BDSRA)

Why are advocacy and accessibility so important to rare diseases such as Batten Disease? On this week’s Few & Far Between podcast episode, Biorasi’s...

Listen

Episode 14

November 10, 2021 00:46:16
Episode Cover

Episode 14: Bo Bigelow, Chairman at the Foundation for USP7-Related Diseases, and Trish Flanagan, President at the Yellow Brick Road Project

How will a rare disease diagnosis affect your family? Today's Few & Far Between episode features Bo Bigelow, Chairman at the Foundation for USP7-Related...

Listen

Episode 38

May 23, 2024 00:35:24
Episode Cover

Episode 41: Craig Serra, Head of Clinical Research Scientific and Technical Engagement, Flatiron Health

"It's amazing how many companies there are and how many opportunities for a kind of a match between a human that needs some help...

Listen